Molepolole CRS

Botswana Harvard AIDS Institute Partnership

HIV Infections

Tuberculosis

Infections

Communicable Diseases

Multidrug-Resistant Tuberculosis

Pulmonary Tuberculosis

Rotavirus Infections

Dolutegravir

Isoniazid

Rifapentine

Delamanid

pretomanid

tenofovir

Efavirenz

rilpivirine

tenofovir alafenamide fumarate

National Institute of Allergy and Infectious Diseases (NIAID)

condition

allSponsorName

ViiV Healthcare

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The A5414 study will evaluate whether treatment for drug-susceptible pulmonary tuberculosis (TB) can be tailored according to a participant's risk of an unfavorable outcome. Participants will be assigned to lower-risk or higher-risk groups using baseline characteristics and then randomized within each group to receive either standard TB treatment or an investigational rifapentine- and moxifloxacin-containing regimen. The study will evaluate whether shorter treatment durations may be used in lower-risk participants and whether the investigational regimen may improve outcomes in higher-risk participants. Safety and tolerability will also be evaluated.

A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

Botswana Harvard AIDS Institute Partnership | Molepolole CRS

Site insights

Work at this site?

Active trials

A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

Trial sponsors